Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A. Rody A, et al. Among authors: ruckhaberle e. Zentralbl Gynakol. 2006 Apr;128(2):76-81. doi: 10.1055/s-2006-921508. Zentralbl Gynakol. 2006. PMID: 16673249 Clinical Trial.
ABC7 Consensus: Assessment by a German Group of Experts.
Ditsch N, Untch M, Fasching PA, Busch S, Ettl J, Haidinger R, Jackisch C, Lüftner D, Müller L, Müller V, Ruckhäberle E, Schumacher-Wulf E, Thomssen C, Harbeck N, Wuerstlein R. Ditsch N, et al. Among authors: ruckhaberle e. Breast Care (Basel). 2024 Apr;19(2):116-128. doi: 10.1159/000535997. Epub 2024 Jan 24. Breast Care (Basel). 2024. PMID: 38638343 Free article.
Is the (Neo)adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering?: Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer.
Krawczyk N, Ruckhäberle E, Lux MP, Fehm T, Greiling M, Osygus M. Krawczyk N, et al. Among authors: ruckhaberle e. Geburtshilfe Frauenheilkd. 2022 Nov 30;83(3):321-332. doi: 10.1055/a-1921-9336. eCollection 2023 Mar. Geburtshilfe Frauenheilkd. 2022. PMID: 36908284 Free PMC article.
Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.
Rody A, Karn T, Gätje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhäberle E, Holtrich U, von Minckwitz G, Kaufmann M. Rody A, et al. Among authors: ruckhaberle e. Breast. 2007 Feb;16(1):86-93. doi: 10.1016/j.breast.2006.06.008. Epub 2006 Sep 28. Breast. 2007. PMID: 17010609 Clinical Trial.
Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1.
Rody A, Holtrich U, Gaetje R, Gehrmann M, Engels K, von Minckwitz G, Loibl S, Diallo-Danebrock R, Ruckhäberle E, Metzler D, Ahr A, Solbach C, Karn T, Kaufmann M. Rody A, et al. Among authors: ruckhaberle e. Clin Cancer Res. 2007 Feb 15;13(4):1115-22. doi: 10.1158/1078-0432.CCR-06-2433. Clin Cancer Res. 2007. PMID: 17317819
The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial.
Rody A, Karn T, Solbach C, Gaetje R, Munnes M, Kissler S, Ruckhäberle E, Minckwitz GV, Loibl S, Holtrich U, Kaufmann M. Rody A, et al. Among authors: ruckhaberle e. Breast. 2007 Jun;16(3):235-40. doi: 10.1016/j.breast.2007.02.006. Epub 2007 Apr 20. Breast. 2007. PMID: 17449250
67 results